Hemostasis abnormalities in liver cirrhosis: Myth or reality?

Polskie Archiwum Medycyny Wewnetrznej

Volumn 118, Issue 7-8, 2008, Pages 445-448

  Tripodi, Armando ^a  

^a FONDAZIONE IRCCS CA GRANDA OSPEDALE MAGGIORE POLICLINICO   (Italy)

Author keywords

Chronic liver disease; Coagulation; Coagulopathy; Liver transplantation; Prognosis

Indexed keywords

BLOOD CLOTTING FACTOR 8; DESMOPRESSIN; PLASMINOGEN; TISSUE PLASMINOGEN ACTIVATOR;

BLEEDING; BLOOD CLOTTING; FIBRINOLYSIS; HEMOSTASIS; HUMAN; LABORATORY TEST; LIVER CIRRHOSIS; PARTIAL THROMBOPLASTIN TIME; PROTHROMBIN TIME; REVIEW; RISK FACTOR;

EID: 49249083985     PISSN: 00323772     EISSN: None     Source Type: Journal    
DOI: 10.20452/pamw.448     Document Type: Review

References (19)

1. Caldwell SH, Hoffman M, Lisman T, et al. Coagulation disorders and hemostasis in liver disease: pathophysiology and critical assessment of current management. Hepatology. 2006; 44: 1039-1046.
2. Violi F, Leo R, Vezza E, et al. Bleeding time in patients with cirrhosis: relation with degree of liver failure and clotting abnormalities. CALC Group. Coagulation Abnormalities in Cirrhosis Study Group. J Hepatol. 1994; 20: 531-536.
3. Boberg KM, Brosstad F, Egeland T, et al. Is a prolonged bleeding time associated with an increased risk of hemorrhage after liver biopsy? Thromb Haemost. 1999; 81: 378-381.
4. Mannucci PM, Vicente V, Vianello L, et al. Controlled trial of desmopressin in liver cirrhosis and other conditions associated with a prolonged bleeding time. Blood. 1986; 67: 1148-1153.
5. Burroughs AK, Matthews K, Qadiri M, et al. Desmopressin and bleeding time in patients with cirrhosis. Br Med J. 1985; 291: 1377-1381.
6. de Franchis R, Arcidiacono PG, Carpinelli L, et al. Randomized controlled trial of desmopressin plus terlipressin vs terlipressin alone for the treatment of acute variceal hemorrhage in cirrhotic patients: a multicenter, double-blind study. New Italian Endoscopic Club. Hepatology. 1993; 18: 1102-1107.
7. Wong AY, Irwin MG, Hui TW, et al. Desmopressin does not decrease blood loss and transfusion requirements in patients undergoing hepatectomy. Can J Anaesth. 2003; 50: 14-20.
8. Lisman T, Bongers TN, Adelmeijer J, et al. Elevated levels of von Willebrand Factor in cirrhosis support platelet adhesion despite reduced functional capacity. Hepatology. 2006; 44: 53-61.
9. Lisman T, Leebeek FW, Mosnier LO, et al. Thrombin-activatable fibrinolysis inhibitor deficiency in cirrhosis is not associated with increased plasma fibrinolysis. Gastroenterology. 2001; 121: 131-139.
10. Colucci M, Binetti BM, Branca MG, et al. Deficiency of thrombin activatable fibrinolysis inhibitor in cirrhosis is associated with increased plasma fibrinolysis. Hepatology. 2003; 38: 230-237.
11. Hedner U, Erhardtsen E. Hemostatic disorders in liver disease. In: Schiff ER, Sorrell MF, Maddrey WC, eds. Schiff's disease of the liver. Philadelphia, Lippincott Williams & Wilkins, 2003: 625-636.
12. Tripodi A, Caldwell SH, Hoffman M, et al. The prothrombin time test as a measure of bleeding risk and prognosis in liver disease. Aliment Pharmacol Ther. 2007; 26: 141-148.
13. Tripodi A, Salerno F, Chantarangkul V, et al. Evidence of normal thrombin generation in cirrhosis despite abnormal conventional coagulation tests. Hepatology. 2005; 41: 553-558.
14. Bevers EM, Comfurius P, Zwaal RF. Platelet procoagulant activity: physiological significance and mechanisms of exposure. Blood Rev. 1991; 5: 146-154.
15. Tripodi A, Primignani M, Chantarangkul V, et al. Thrombin generation in patients with cirrhosis: the role of platelets. Hepatology. 2006; 44: 440-445.
16. Bosch J, Thabut D, Bendtsen F, et al.; European Study Group on rFVIIa in UGI Haemorrhage. Recombinant factor VIIa for upper gastrointestinal bleeding in patients with cirrhosis: a randomized, double-blind trial. Gastroenterology. 2004; 127: 1123-1130.
17. Lodge JP, Jonas S, Jones RM, et al.; rFVIIa OLT Study Group. Efficacy and safety of repeated perioperative doses of recombinant factor VIIa in liver transplantation. Liver Transpl. 2005; 11: 973-979.
18. Planinsic RM, van der Meer J, Testa G, et al. Safety and efficacy of a single bolus administration of recombinant factor VIIa in liver transplantation due to chronic liver disease. Liver Transpl. 2005; 11: 895-900.
19. Peck-Radosavljevic M, Wichlas M, Zacherl J, et al. Thrombopoietin induces rapid resolution of thrombocytopenia after orthotopic liver transplantation through increased platelet production. Blood. 2000; 95: 795-801.